Decitabine/Cedazuridine - Astex Pharmaceuticals

Drug Profile

Decitabine/Cedazuridine - Astex Pharmaceuticals

Alternative Names: ASTX 727; Cedazuridine/Decitabine; Decitabine/E7727; E-7727/decitabine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astex Pharmaceuticals
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Cytidine deaminase inhibitors; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 13 Oct 2017 Astex Pharmaceuticals plans a phase III trial for Myelodysplastic-syndromes and Chronic myelomonocytic leukaemia in USA (PO) (NCT03306264)
  • 22 Jun 2017 Phase-II clinical trials in Chronic myelomonocytic leukaemia in USA before June 2017 (PO)
  • 22 Jun 2017 Phase-II clinical trials in Myelodysplastic syndromes in USA before June 2017 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top